Alginate encapsulant incorporating CXCL12 supports long-term allo- and xenoislet transplantation without systemic immune suppression

American Journal of Transplantation

Volumn 15, Issue 3, 2015, Pages 618-627

  Chen, T ^a   Yuan, J ^a   Duncanson, S ^b   Hibert, M L ^a   Kodish, B C ^a   Mylavaganam, G ^a   Maker, M ^a   Li, H ^a   Sremac, M ^a   Santosuosso, M ^a   Forbes, B ^a   Kashiwagi, S ^a   Cao, J ^a   Lei, J ^c   Thomas, M ^a   Hartono, C ^d   Sachs, D ^a   Markmann, J ^e   Sambanis, A ^b   Poznansky, Mark C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c Department of Transplantation Surgery ^*  (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Georgia Institute of Technology   (United States)

Author keywords

animal models; basic (laboratory) research science; kidney biology; kidney transplantation nephrology; xenotransplantation

Indexed keywords

ALGINIC ACID; IMMUNOSUPPRESSIVE AGENT; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, MOUSE; GLUCURONIC ACID; HEXURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ENCAPSULATION; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM SURVIVAL; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTEMIC THERAPY; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; XENOGRAFT;

ALGINATES; ANIMALS; CHEMOKINE CXCL12; FEMALE; GLUCURONIC ACID; HETEROGRAFTS; HEXURONIC ACIDS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; TRANSPLANTATION, HOMOLOGOUS;

EID: 84923228705     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13049     Document Type: Article

References (52)

1. Ramesh A, Chhabra P, Brayman KL., Pancreatic islet transplantation in type 1 diabetes mellitus: An update on recent developments. Curr Diabetes Rev 2013; 9: 294-311.
2. Shapiro AMJ, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-1330.
3. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci USA 2013; 110: 19054-19058.
4. Robertson RP., Islet transplantation as a treatment for diabetes-A work in progress. N Engl J Med 2004; 350: 694-705.
5. Bellin MD, Beilman GJ, Dunn TB, et al. Islet autotransplantation to preserve beta cell mass in selected patients with chronic pancreatitis and diabetes mellitus undergoing total pancreatectomy. Pancreas 2013; 42: 317-321.
6. Abreu JRF, Roep BO., Immune monitoring of islet and pancreas transplant recipients. Curr Diab Rep 2013; 13: 704-712.
7. Vantyghem M-C, Mathurin P, Hober D, et al. Partial graft recovery following eradication of hepatitis E virus infection after successful islet allograft transplantation. Transpl Int 2011; 24: e13-e15.
8. Hafiz MM, Faradji RN, Froud T, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005; 80: 1718-1728.
9. Mallett AG, Korbutt GS., Alginate modification improves long-term survival and function of transplanted encapsulated islets. Tissue Eng Part A 2009; 15: 1301-1309.
10. Sakata N, Sumi S, Yoshimatsu G, Goto M, Egawa S, Unno M., Encapsulated islets transplantation: Past, present and future. World J Gastrointest Pathophysiol 2012; 3: 19-26.
11. Khattar M, Deng R, Kahan BD, et al. Novel sphingosine-1-phosphate receptor modulator KRP203 combined with locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts. Transplantation 2013; 95: 919-927.
12. Luca G, Fallarino F, Calvitti M, et al. Xenograft of microencapsulated sertoli cells reverses T1DM in NOD mice by inducing neogenesis of beta-cells. Transplantation 2010; 90: 1352-1357.
13. Yin Z, Chen D, Hu F, et al. Cotransplantation with xenogenetic neonatal porcine sertoli cells significantly prolongs islet allograft survival in nonimmunosuppressive rats. Transplantation 2009; 88: 339-345.
14. Domínguez-Bendala J, Lanzoni G, Inverardi L, Ricordi C., Concise review: Mesenchymal stem cells for diabetes. Stem Cells Transl Med 2012; 1: 59-63.
15. Chang C, Niu D, Zhou H, Li F, Gong F., Mesenchymal stem cells contribute to insulin-producing cells upon microenvironmental manipulation in vitro. Transplant Proc 2007; 39: 3363-3368.
16. Papeta N, Chen T, Vianello F, et al. Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent. Transplantation 2007; 83: 174-183.
17. Righi E, Kashiwagi S, Yuan J, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011; 71: 5522-5534.
18. McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS., CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 8053-8064.
19. Cowley MJ, Weinberg A, Zammit NW, et al. Human islets express a marked proinflammatory molecular signature prior to transplantation. Cell Transplant 2012; 21: 2063-2078.
20. Jin DK, Shido K, Kopp H-G, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12: 557-567.
21. Castilla DM, Liu Z-J, Tian R, Li Y, Livingstone AS, Velazquez OC., A novel autologous cell-based therapy to promote diabetic wound healing. Ann Surg 2012; 256: 560-572.
22. Xu X, Zhu F, Zhang M, et al. Stromal cell-derived factor-1 enhances wound healing through recruiting bone marrow-derived mesenchymal stem cells to the wound area and promoting neovascularization. Cells Tissues Organs (Print) 2013; 197: 103-113.
23. Liu Z, Habener JF., Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia 2009; 52: 1589-1598.
24. Pelletier AJ, van der Laan LJ, Hildbrand P, et al. Presentation of chemokine SDF-1 alpha by fibronectin mediates directed migration of T cells. Blood 2000; 96: 2682-2690.
25. Dotan I, Werner L, Vigodman S, et al. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16: 583-592.
26. Karin N., The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J Leukoc Biol 2010; 88: 463-473.
27. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N., CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med 2008; 205: 2643-2655.
28. Datta A, David R, Glennie S, et al. Differential effects of immunosuppressive drugs on T-cell motility. Am J Transplant 2006; 6: 2871-2883.
29. Yu L, Robles DT, Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000; 97: 1701-1706.
30. Eisenbarth GS., Insulin autoimmunity: Immunogenetics/immunopathogenesis of type 1A diabetes. Ann N Y Acad Sci 2003; 1005: 109-118.
31. Bonifacio E, Atkinson M, Eisenbarth G, et al. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: Identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice, 2001, pp. 2451-2458.
32. Wang Y, Irvine DJ., Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres. Biomaterials 2011; 32: 4903-4913.
33. Xiao Q, Ye S, Oberhollenzer F, et al. SDF1 gene variation is associated with circulating SDF1alpha level and endothelial progenitor cell number: The Bruneck Study. PLoS ONE 2008; 3: e4061.
34. Yano T, Liu Z, Donovan J, Thomas MK, Habener JF., Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt. Diabetes 2007; 56: 2946-2957.
35. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-, SDF-1-deficient mice. Proc Natl Acad Sci USA 1998; 95: 9448-9453.
36. Poznansky MC, Olszak IT, Evans RH, et al. Thymocyte emigration is mediated by active movement away from stroma-derived factors. J Clin Invest 2002; 109: 1101-1110.
37. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT., Active movement of T cells away from a chemokine. Nat Med 2000; 6: 543-548.
38. Netelenbos T, Zuijderduijn S, Van Den Born J, et al. Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells. J Leukoc Biol 2002; 72: 353-362.
39. Piccirillo CA., Regulatory T cells in health and disease. Cytokine 2008; 43: 395-401.
40. Xia G, Shah M, Luo X., Prevention of allograft rejection by amplification of Foxp3(+)CD4(+)CD25(+) regulatory T cells. Transl Res 2009; 153: 60-70.
41. Wood KJ., Regulatory T cells in transplantation. Transplant Proc 2011; 43: 2135-2136.
42. Feng G, Wood KJ, Bushell A., Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: Potential avenues for cellular therapy. Transplantation 2008; 86: 578-589.
43. Richer MJ, Lavallée DJ, Shanina I, Horwitz MS., Immunomodulation of antigen presenting cells promotes natural regulatory T cells that prevent autoimmune diabetes in NOD mice. PLoS ONE 2012; 7: e31153.
44. Tonkin DR, He J, Barbour G, Haskins K., Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo. J Immunol 2008; 181: 4516-4522.
45. Hire K, Ngo DK, Stewart-Maynard KM, Hering B, Bansal-Pakala P., FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy. Cell Immunol 2012; 274: 83-88.
46. Shi Q, Lees JR, Scott DW, Farber DL, Bartlett ST., Endogenous expansion of regulatory T cells leads to long-term islet graft survival in diabetic NOD mice. Am J Transplant 2012; 12: 1124-1132.
47. Francis RS, Feng G, Tha-In T, Lyons IS, Wood KJ, Bushell A., Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol 2011; 41: 726-738.
48. Chen D, Zhang N, Fu S, et al. CD4+ CD25+ regulatory T-cells inhibit the islet innate immune response and promote islet engraftment. Diabetes 2006; 55: 1011-1021.
49. Marek N, Krzystyniak A, Ergenc I, et al. Coating human pancreatic islets with CD4(+)CD25(high)CD127(-) regulatory T cells as a novel approach for the local immunoprotection. Ann Surg 2011; 254: 512-518; discussion 518-9.
50. Yolcu ES, Zhao H, Bandura-Morgan L, et al. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J Immunol 2011; 187: 5901-5909.
51. Jaafar F, Righi E, Lindstrom V, et al. Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol 2009; 175: 1525-1535.
52. Zou L, Barnett B, Safah H, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451-8455.